Fiche publication
Date publication
avril 2025
Journal
Drugs in R&D
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
,
Dr DETAPPE Alexandre
,
Dr COLIAT Pierre
Tous les auteurs :
Bischoff H, O'Connor NK, Kim J, Popescu BV, Bigot C, Pradhan S, Chakraborty R, Jaison L, Majeed F, Park LS, Boudali L, Detappe A, Pivot X, Coliat P
Lien Pubmed
Résumé
The high cost of trastuzumab (Herceptin) limits its accessibility for patients worldwide. Biosimilars, such as Tuznue (HD201), represent a promising alternative to improve access to this essential therapy for HER2-positive breast cancer. This study aims to assess the similarity of Tuznue with the reference product Herceptin through comprehensive analytical and biofunctional evaluations, ensuring similar quality, safety, and efficacy profiles.
Référence
Drugs R D. 2025 04 2;:
